Is VALN or KOD more profitable?

Kodiak Sciences has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% Kodiak Sciences N/A -273.23% -85.48%

Does the media prefer VALN or KOD?

In the previous week, Kodiak Sciences had 8 more articles in the media than Valneva. MarketBeat recorded 18 mentions for Kodiak Sciences and 10 mentions for Valneva. Valneva's average media sentiment score of 0.01 beat Kodiak Sciences' score of -0.05 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VALN or RARE?

In the previous week, Ultragenyx Pharmaceutical had 22 more articles in the media than Valneva. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 10 mentions for Valneva. Ultragenyx Pharmaceutical's average media sentiment score of 1.04 beat Valneva's score of 0.01 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 20 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, VALN or NKTR?

Valneva has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 3.34 -$130.33M -$2.11 N/A Nektar Therapeutics $55.23M 45.75 -$164.08M -$6.70 N/A

Is VALN or NKTR more profitable?

Valneva has a net margin of -110.33% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% Nektar Therapeutics -287.84% -37.87% -25.67%

Does the media prefer VALN or NKTR?

In the previous week, Nektar Therapeutics had 12 more articles in the media than Valneva. MarketBeat recorded 22 mentions for Nektar Therapeutics and 10 mentions for Valneva. Nektar Therapeutics' average media sentiment score of 0.44 beat Valneva's score of 0.01 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer VALN or BCRX?

In the previous week, Valneva had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 10 mentions for Valneva and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.95 beat Valneva's score of 0.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COAG or VALN?

In the previous week, Valneva had 8 more articles in the media than Hemab Therapeutics. MarketBeat recorded 10 mentions for Valneva and 2 mentions for Hemab Therapeutics. Valneva's average media sentiment score of 0.01 beat Hemab Therapeutics' score of 0.00 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valneva 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valneva (VALN) Competitors

$6.96 +0.14 (+2.05%)

As of 08/21/2026 04:00 PM Eastern

Compare

VALN vs. KOD, RARE, NKTR, BCRX, and COAG

Should you buy Valneva stock or one of its competitors? Valneva's main competitors and comparable companies include Kodiak Sciences (KOD), Ultragenyx Pharmaceutical (RARE), Nektar Therapeutics (NKTR), BioCryst Pharmaceuticals (BCRX), and Hemab Therapeutics (COAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valneva compare to Kodiak Sciences?

Valneva (NASDAQ:VALN) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Valneva has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

11.4% of Valneva shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valneva presently has a consensus target price of $11.98, suggesting a potential upside of 72.13%. Kodiak Sciences has a consensus target price of $48.14, suggesting a potential upside of 25.60%. Given Valneva's higher probable upside, research analysts plainly believe Valneva is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Kodiak Sciences had 8 more articles in the media than Valneva. MarketBeat recorded 18 mentions for Kodiak Sciences and 10 mentions for Valneva. Valneva's average media sentiment score of 0.01 beat Kodiak Sciences' score of -0.05 indicating that Valneva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.34	-$130.33M	-$2.11	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Kodiak Sciences has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Kodiak Sciences	N/A	-273.23%	-85.48%

Summary

Valneva beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does Valneva compare to Ultragenyx Pharmaceutical?

Valneva (NASDAQ:VALN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

11.4% of Valneva shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valneva has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.34	-$130.33M	-$2.11	N/A
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$5.84	N/A

Valneva currently has a consensus target price of $11.98, suggesting a potential upside of 72.13%. Ultragenyx Pharmaceutical has a consensus target price of $58.89, suggesting a potential upside of 127.99%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

In the previous week, Ultragenyx Pharmaceutical had 22 more articles in the media than Valneva. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 10 mentions for Valneva. Ultragenyx Pharmaceutical's average media sentiment score of 1.04 beat Valneva's score of 0.01 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats Valneva on 10 of the 17 factors compared between the two stocks.

How does Valneva compare to Nektar Therapeutics?

Valneva (NASDAQ:VALN) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Nektar Therapeutics had 12 more articles in the media than Valneva. MarketBeat recorded 22 mentions for Nektar Therapeutics and 10 mentions for Valneva. Nektar Therapeutics' average media sentiment score of 0.44 beat Valneva's score of 0.01 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Valneva presently has a consensus price target of $11.98, suggesting a potential upside of 72.13%. Nektar Therapeutics has a consensus price target of $141.50, suggesting a potential upside of 91.16%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Valneva has a net margin of -110.33% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Valneva has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.34	-$130.33M	-$2.11	N/A
Nektar Therapeutics	$55.23M	45.75	-$164.08M	-$6.70	N/A

11.4% of Valneva shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valneva has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Summary

Nektar Therapeutics beats Valneva on 9 of the 16 factors compared between the two stocks.

How does Valneva compare to BioCryst Pharmaceuticals?

Valneva (NASDAQ:VALN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

BioCryst Pharmaceuticals has higher revenue and earnings than Valneva. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.34	-$130.33M	-$2.11	N/A
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A

Valneva currently has a consensus target price of $11.98, suggesting a potential upside of 72.13%. BioCryst Pharmaceuticals has a consensus target price of $20.60, suggesting a potential upside of 115.48%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Valneva had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 10 mentions for Valneva and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.95 beat Valneva's score of 0.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Valneva's net margin of -110.33%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

11.4% of Valneva shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valneva has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Valneva compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Valneva (NASDAQ:VALN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Hemab Therapeutics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Valneva	$197.56M	3.34	-$130.33M	-$2.11	N/A

In the previous week, Valneva had 8 more articles in the media than Hemab Therapeutics. MarketBeat recorded 10 mentions for Valneva and 2 mentions for Hemab Therapeutics. Valneva's average media sentiment score of 0.01 beat Hemab Therapeutics' score of 0.00 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hemab Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Hemab Therapeutics' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Valneva	-110.33%	-153.20%	-39.50%

Hemab Therapeutics currently has a consensus target price of $51.40, suggesting a potential upside of 4.56%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 72.13%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Valneva beats Hemab Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$660.41M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-3.30	11.62	272.60	24.24
Price / Sales	3.34	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	7.03	16.80	13.05	6.20
Net Income	-$130.33M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-2.38%	3.29%	2.09%	0.08%
1 Month Performance	45.61%	8.23%	6.64%	3.88%
1 Year Performance	-40.21%	55.05%	25.02%	16.98%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	2.4129 of 5 stars	$6.96 +2.1%	$11.98 +72.1%	-40.2%	$660.41M	$197.56M	N/A	700	Analyst Revision
KOD Kodiak Sciences	2.5356 of 5 stars	$40.66 -0.8%	$48.14 +18.4%	+275.8%	$2.54B	N/A	N/A	90	News Coverage Analyst Revision Gap Down
RARE Ultragenyx Pharmaceutical	3.442 of 5 stars	$25.49 -2.4%	$57.82 +126.8%	-13.3%	$2.51B	$673M	N/A	1,371	Trending News Analyst Forecast
NKTR Nektar Therapeutics	2.915 of 5 stars	$73.74 +1.5%	$150.00 +103.4%	+173.8%	$2.49B	$54.59M	N/A	220	Trending News Analyst Forecast Analyst Revision
BCRX BioCryst Pharmaceuticals	2.8354 of 5 stars	$9.70 -2.4%	$20.60 +112.4%	+11.7%	$2.48B	$874.84M	N/A	530

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors

VALN vs. KOD, RARE, NKTR, BCRX, and COAG

How does Valneva compare to Kodiak Sciences?

Summary

How does Valneva compare to Ultragenyx Pharmaceutical?

Summary

How does Valneva compare to Nektar Therapeutics?

Summary

How does Valneva compare to BioCryst Pharmaceuticals?

Summary

How does Valneva compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valneva (VALN) Competitors

VALN vs. KOD, RARE, NKTR, BCRX, and COAG

How does Valneva compare to Kodiak Sciences?

Which has more risk & volatility, VALN or KOD?

Do insiders & institutionals hold more shares of VALN or KOD?

Do analysts rate VALN or KOD?

Does the media prefer VALN or KOD?

Which has higher earnings and valuation, VALN or KOD?

Is VALN or KOD more profitable?

Summary

How does Valneva compare to Ultragenyx Pharmaceutical?

Is VALN or RARE more profitable?

Do insiders & institutionals hold more shares of VALN or RARE?

Which has stronger earnings and valuation, VALN or RARE?

Do analysts prefer VALN or RARE?

Does the media prefer VALN or RARE?

Which has more volatility & risk, VALN or RARE?

Summary

How does Valneva compare to Nektar Therapeutics?

Does the media prefer VALN or NKTR?

Do analysts prefer VALN or NKTR?

Is VALN or NKTR more profitable?

Which has better valuation and earnings, VALN or NKTR?

Do institutionals and insiders hold more shares of VALN or NKTR?

Which has more risk and volatility, VALN or NKTR?

Summary

How does Valneva compare to BioCryst Pharmaceuticals?

Which has higher earnings & valuation, VALN or BCRX?

Do analysts rate VALN or BCRX?

Does the media prefer VALN or BCRX?

Is VALN or BCRX more profitable?

Do institutionals & insiders hold more shares of VALN or BCRX?

Which has more risk & volatility, VALN or BCRX?

Summary

How does Valneva compare to Hemab Therapeutics?

Which has better earnings & valuation, COAG or VALN?

Does the media refer more to COAG or VALN?

Do institutionals and insiders have more ownership in COAG or VALN?

Is COAG or VALN more profitable?

Do analysts rate COAG or VALN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools